TF0023 for Coronavirus Pneumonia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Coronavirus PneumoniaTF0023 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it can help relieve symptoms of ARDS and pneumonia caused by COVID-19.

Eligible Conditions
  • Coronavirus Pneumonia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
DVX201
1
AT-100
1
APN01

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 28 days

15 days
Percentage of patients able to maintain peripheral capillary oxygen saturation (SpO2) of >93% without oxygen support at Day 15.
28 days
All-cause mortality
Changes of chest x-ray, and computerized tomography (CT) scan
Changes of clinical status (9-point ordinal scale)
Cumulative incidence of SAEs, Grade 3 and 4 clinical and/or laboratory AEs
Duration of hospitalization and duration of Intensive Care Unit (ICU) treatment
Incidence and duration of new mechanical ventilation use and on respiratory failure-free days
Number of supplemental oxygen-free days between Day 1 and Day 29.
Pattern score and volumetric score of the radiologic severity index.
Percentage of patients reporting each severity rating on the 9-point ordinal scale
Time to not requiring oxygen support.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
DVX201
1
AT-100
2
APN01

Trial Design

4 Treatment Groups

Low Dose Placebo Control
1 of 4
Low Dose of Active Drug
1 of 4
High Dose of Active Drug
1 of 4
High Dose Placebo Control
1 of 4

Experimental Treatment

400 Total Participants · 4 Treatment Groups

Primary Treatment: TF0023 · No Placebo Group · Phase 2

Low Dose Placebo Control
Drug
Experimental Group · 1 Intervention: TF0023 · Intervention Types: Drug
Low Dose of Active Drug
Drug
Experimental Group · 1 Intervention: TF0023 · Intervention Types: Drug
High Dose of Active Drug
Drug
Experimental Group · 1 Intervention: TF0023 · Intervention Types: Drug
High Dose Placebo Control
Drug
Experimental Group · 1 Intervention: TF0023 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Techfields IncLead Sponsor
1 Previous Clinical Trials
225 Total Patients Enrolled
Chongxi Yu, Ph.DStudy ChairTechfields Inc
1 Previous Clinical Trials
225 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are admitted to a hospital with pulmonary symptoms of active COVID-19.
You understand and agree to comply with the study's planned procedures.
You agree to not participate in another clinical study for the treatment of COVID-19 or SARS-CoV-2 through Day 29.
You are of childbearing potential and you agree to either abstinence or use at least 1 primary form of contraception from the time of screening through Day 29.

Who else is applying?

What state do they live in?
Virginia100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top